Document is current
Any future updates will be listed below
-
Authors
Hennequart, Marc https://orcid.org/0000-0003-4360-6830
Mervant, Loic
Stockis, Julie https://orcid.org/0000-0003-4911-6891
Coomes, Jack
Zarou, Martha M.
Gerard, Louise
Tevel, Virginie
Migeot, Valérie
Pilley, Steven E. https://orcid.org/0000-0001-9670-3314
Lee, Younghwan
Driscoll, Paul C. https://orcid.org/0000-0002-4124-6950
Legrave, Nathalie M. https://orcid.org/0000-0003-1172-4955
Labuschagne, Christiaan F. https://orcid.org/0000-0001-9474-5174
Zani, Fabio
Uribe, Alejandro Huerta
Ferreira, Rute Machado De Morais
Cheung, Eric C.
Malanchi, Ilaria
MacRae, James I. https://orcid.org/0000-0002-1464-8583
Maddocks, Oliver D. K. https://orcid.org/0000-0002-5551-9091
Halim, Timotheus Y. F. https://orcid.org/0000-0001-9773-0023
Vousden, Karen H. https://orcid.org/0000-0002-7365-1766
- License Information
-
More Information
Article History
Received: 30 October 2024
Accepted: 7 January 2026
First Online: 1 April 2026
Competing interests
: K.H.V. is on the board of directors and shareholder of Bristol Myers Squibb and on the science advisory board (with stock options) of PMV Pharma, RAZE Therapeutics, Volastra Pharmaceuticals and Kovina Therapeutics. She is on the SAB of Ludwig Cancer and a co-founder and consultant of Faeth Therapeutics. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to CRUK Cancer Research Technology filing of patent application WO/2017/144877. O.D.K.M. is a board member, shareholder and paid advisor of Faeth Therapeutics. The other authors have no conflicts to disclose.
